#China #Veterinary Vaccines #Jilin #Zhengye Biotechnology #Swine Market

Zhengye Biotechnology Holdings Limited Reports Fiscal Year 2025 Financial Results

Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT), known for its veterinary vaccine production, has announced its financial results for the fiscal year ending December 31, 2025. The company has primarily focused on researching, developing, manufacturing, and selling vaccines aimed at livestock health.

A Year of Resilience

Mr. Songlin Song, co-CEO, expressed optimism despite facing significant market challenges, particularly within the hog sector characterized by fluctuating prices and government control measures. He emphasized the company's commitment to executing its long-term value creation strategy and noted positive developments in their other vaccine segments, notably those for sheep, which have positively impacted revenue distribution.

Zhengye's international ambitions continue to grow, as it seeks to register vaccines in overseas markets such as Egypt, Pakistan, and Vietnam, enhancing its expansion strategy further.

Commitment to Innovation

The focus on research and development remains robust. In 2025, Zhengye reached several crucial milestones, including the approval of two National Category I New Veterinary Drugs and one National Category III New Veterinary Drug by China's Ministry of Agriculture and Rural Affairs. Additionally, Zhengye obtained product approvals for various animal species, expanding its vaccine portfolio significantly. This innovation reflects the company's efforts in strengthening its market position and catering to increasing demands across species.

Financial Highlights

The financial report reveals that Zhengye's net revenue for the fiscal year 2025 was RMB116.4 million (approximately $16.6 million), a decrease from the previous year’s RMB186.4 million. The gross profit also saw a decline, dropping to RMB23.9 million from RMB91.3 million in 2024, leading to a gross profit margin reduction to 20.5%.

Operating expenses soared to RMB94.4 million, primarily driven by increased sales, marketing, and administrative expenses attributable to higher payroll and advertising costs. Zhengye reported a net loss of RMB83.0 million compared to a net income of RMB13.5 million from 2024, which translates to a basic and diluted loss per share of RMB1.47.

Despite these financial hurdles, Zhengye ended the year with a stronger cash position at RMB50.3 million, indicating a positive trend that may support future investments.

Looking Forward

As the company looks toward a more promising future, early indicators suggest a gradual recovery in the swine market with expectations of price improvements in mid-2026.

Zhengye aims to deepen customer relationships, enhance its product portfolio, and expand its service ecosystem. It is also exploring entry into the companion animal market, looking for new growth avenues while navigating industry cycles.

Mr. Aiden Han, co-CEO, reinforced that their Nasdaq listing has fortified the company's financial stability, positioning Zhengye favorably to pursue its strategic goals while thanking shareholders and partners for their continuous support.

Conclusion

While FY 2025 presented various challenges, Zhengye Biotechnology Holding Limited remains committed to its vision of growth through innovation and strategic expansion, laying a solid foundation for future successes in the veterinary vaccine landscape. Opportunities in international markets and a strengthened research-driven approach could play pivotal roles in the company’s recovery and long-term development.